Clinical Trial Results: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating cemiplimab in combination with platinum-based chemotherapy for non-small cell lung cancer have been completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (cemiplimab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2026-04-29